Could we change the course of MASLD - what is available and what is in the pipeline? @EASDiabetes
Could we change the course of MASLD - what is available and what is in the pipeline? @EASDiabetes
Uploaded March 2026 | Updated September 2026, 3 days ago
In this EASD Early Career Academy webinar, Prof. Amalia Gastaldelli (National Research Council, Italy) discussed what's driving MASLD at a pathophysiological level, where current treatments stand and what's in the pipeline. From metabolic to inflammatory to fibrotic targets and whether any of this can genuinely shift long-term outcomes.
#MASLD #liver #diabetes #weightloss #bariatricsurgery #fibrosis
Could we change the course of MASLD - what is available and what is in the pipeline?EASD 2025: Back to the Future: Re-centring the Role of the Pancreas in Type 2 Diabetes11th ECA Journal Club - Tracking metabolic phenotypes in preclinical type 1 diabetes#EASD2022 Wrap-up and highlight with Luigi Gnudi and Leszek CzupryniakEASD 2024 - Can Pre-diabetes Remission Reduce Global Diabetes Incidence?EASD2025: Dementia in Diabetes: Reasons for Hope or ConcernEASD 2025: Update of the Consensus Report on the Management of Type 1 Diabetes in Adults#EASD2022 Interview with the EFSD Novo Nordisk Foundation Future LeadersEASD 2024 - Global Perspectives on DiabetesMeet the EASD Early Career Academy - Introducing Agata Grzelka-Wozniak1st EASD Early Career Academy Webinar: Science communication masterclassEASD2025: Tailored Nutrition and Low-Calorie Diet Remission Updates
European Association for the Study of Diabetes |

Could we change the course of MASLD - what is available and what is in the pipeline?

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER